NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

3 Months Ended

Dec. 31, 2021

6. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of December 31,		As of September 30,
	2021		2021
Accrued compensation and benefits	$	1,095,617	$	880,707
Accrued consulting settlement		300,000		200,000
Accrued professional fees		203,816		299,557
Accrued research and development		720,875		297,047
Accrued franchise tax		77,120		30,720
Other accrued expenses		15,452		39,715
Total	$	2,412,880	$	1,747,746